European Commission launches eligibility checker for EU Joint Clinical Assessments

The new tool is intended to help health technology developers determine whether a medicinal product falls within the EU’s Joint Clinical Assessment requirements before entering the formal HTA process.

The European Commission has launched a Joint Clinical Assessment eligibility checker to help health technology developers assess whether their medicinal products are subject to JCA under the EU Health Technology Assessment Regulation.

The tool provides developers with an additional way to clarify applicability as the JCA framework expands, although formal assessment procedures and evidence submissions continue through the established EU HTA processes.

Field	Content
Alert Type	Industry Update
Topic	Health technology assessment; Joint Clinical Assessment; market access
Organisation(s)	European Commission; Member State Coordination Group on Health Technology Assessment (HTACG)
Affected Stakeholders	Pharmaceutical and biotechnology companies; health technology developers; market access, HEOR, regulatory and clinical-development teams
Geography	European Union
What Happened	The European Commission has introduced a JCA eligibility checker designed to help health technology developers determine whether a medicinal product is expected to fall within the scope of Joint Clinical Assessment under the EU Health Technology Assessment Regulation. The checker provides an additional practical resource for developers assessing their obligations under the framework. JCA has applied since January 2025, initially covering new oncology medicines containing new active substances and advanced therapy medicinal products, with the scope expanding progressively to additional technologies. (Public Health)
Why It Matters	Determining whether a product falls within JCA scope affects evidence planning, submission preparation and coordination between regulatory and HTA activities. A dedicated eligibility tool could allow developers to identify potential JCA obligations earlier and incorporate the European clinical assessment into development and market-access planning rather than waiting until later in the regulatory process. EMA and the HTA Secretariat have already been working to clarify JCA eligibility assessment, timelines and information exchange between the regulatory and HTA processes. (European Medicines Agency (EMA))
Supporting Context	The EU HTA Regulation established a common European process for assessing the relative clinical effectiveness and safety of technologies within scope, while Member States retain responsibility for national value judgements, pricing and reimbursement decisions. The system is being introduced progressively, meaning determining whether and when an individual product enters scope remains an important planning issue for developers. (Public Health)
Who Is Most Affected	Pharmaceutical and biotechnology developers preparing products that could enter JCA are most directly affected, particularly market access, HEOR, regulatory and clinical-development teams responsible for coordinating evidence requirements and submission timelines.
Industry Impact	The checker should provide greater procedural clarity around whether products are subject to JCA, potentially allowing companies to identify relevant EU HTA requirements earlier. It does not replace the formal JCA process or the need to prepare the required clinical evidence dossier through the EU HTA framework.
Key Takeaway	The Commission’s eligibility checker gives medicine developers a practical early-stage tool for determining whether their products are likely to require an EU Joint Clinical Assessment.
What to Watch	How developers use the checker in practice and further Commission and HTACG guidance as experience with JCA grows and the framework expands to additional categories of health technology.
Primary Source	European Commission – Health Technology Assessment / Joint Clinical Assessments
Relevant Date	August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com